Decreasing early mortality (30-day) in APL patients with use of streamlined treatment guidelines and support from core group of experts.

Anand P. Jillella,Farrukh Tauseef Awan,Jeremy Mark Pantin,Ravindra B. Kolhe,Vamsi Kota

DOI: https://doi.org/10.1200/jco.2013.31.15_suppl.7091

IF: 45.3

2013-05-20

Journal of Clinical Oncology

Abstract:7091 Background: Recent evidence from population based studies in Brazil and US SEER data show that the early mortality (EM) in APL is around 30%. This is in contrast to observation in clinical trials where it is 5%. The common causes of death are hemorrhagic complications (HC), infection, differentiation syndrome (DS) and multi-organ failure. HC are unique to this condition due to DIC and HC are seen in upto 60% of patients. Hence, decreasing early deaths is a high priority at all leukemia treatment centers. We report our updated results showing that use of set of streamlined treatment guidelines along with support from experts decreases early deaths. Methods: At Georgia Regents University, between 7/2005 and 6/2009, 19 patients were diagnosed with APL. 7 patients (5 high-risk and 2 low-risk) died during induction resulting in an unusually high mortality rate of 37%. All patients who survived induction are still in remission at present. The high early death rate prompted us to develop a simple, 2 page treatment algorithm that focuses on quick diagnosis, prompt initiation of therapy, and proactive and aggressive management of all the major causes of death during induction. We also made our treatment protocol available to smaller treatment centers and helped the treating oncologists manage the patient during the first few days after diagnosis. Results: From 11/2010 to 12/2012, we treated 5 patients at GRU and helped manage 9 patients at 5 practices. Age range was 30-60 years. 4 patients were high-risk, 7 intermediate and three low-risk. There were no deaths during induction. Only 1 patient (8%) had HC and 4 had DS. Conclusions: While we recognize that this is a small cohort, our own experience and a similar approach pioneered by investigators in Brazil clearly shows this to be an effective model to decrease early deaths in APL. We believe our experience warrants large scale implementation of our protocol in an attempt to decrease early mortality in APL. We were awarded a 1.68 million grant by the Leukemia Lymphoma Society to implement this protocol in the states of Georgia and South Carolina with a catchment population of 15 million over a 3 year period.

oncology